Summit Therapeutics (SMMT) Net Income towards Common Stockholders (2017 - 2024)

Summit Therapeutics (SMMT) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$72.9 million in Q4 2024.

• Quarterly Net Income towards Common Stockholders fell 86.46% year-over-year to -$72.9 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$72.9 million (up 64.97% YoY) and the FY2024 annual result came in at -$1.9 billion, down 209.59% from the prior year.
• Net Income towards Common Stockholders retreated to -$72.9 million in Q4 2024, from -$60.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$6.3 million in Q1 2020 to a low of -$544.5 million in Q1 2023.
• A 5-year average of -$54.3 million and a median of -$22.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 2324.91% — and 2024, when it surged 91.64%.
• Tracing SMMT's Net Income towards Common Stockholders over 5 years: stood at -$13.5 million in 2020, then slumped by 100.13% to -$27.1 million in 2021, then grew by 14.38% to -$23.2 million in 2022, then tumbled by 68.54% to -$39.1 million in 2023, then tumbled by 86.46% to -$72.9 million in 2024.
• The last three Net Income towards Common Stockholders figures came in at -$72.9 million (Q4 2024), -$60.8 million (Q3 2024), and -$62.7 million (Q2 2024), per Business Quant data.